Skip to main content

Pfizer Venture Investments — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

52
Companies
$2.1B
Total invested
$50.3M
Avg. check
14
Industries
Biotechnology 23Health Care 13Medical 9Therapeutics 9Pharmaceutical 5Life Science 3+8 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 52
MindImmune Therapeutics
March 2026

MindImmune Therapeutics is a pharmaceutical company developing drugs to treat diseases of the central nervous system.

Biotechnology · Providence$5.0M Grant
Enodia Therapeutics
January 2026

Enodia Therapeutics is a biotech company that provides transforming treatments for cancer, inflammation, and viral infection diseases.

Biotechnology · Paris$24.2M Seed
Syneron
December 2025

Syneron is a company that using artificial intelligence and biotechnology to address two significant global challenges.

Artificial Intelligence (AI) · Guangzhou$100.0M Series A
4D Molecular Therapeutics
November 2025

4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.

Biotechnology · Emeryville$100.0M Post Ipo Equity
Crossbow Therapeutics
September 2025

Crossbow Therapeutics is a biotech company developing a new type of cancer treatment.

Biotechnology · Cambridge$30.3M Series Unknown
OTR Therapeutics
June 2025

OTR Therapeutics is a biotechnology company developing platform-based treatments using modular RNA and delivery systems.

Biotechnology · Shanghai$100.0M Series A
TRIMTECH Therapeutics
March 2025

TRIMTECH Therapeutics treats inflammatory and persistent CNS conditions by focusing on the elimination of harmful proteins.

Biotechnology · Cambridge$31.0M Seed
EvolveImmune Therapeutics
October 2024

EvolveImmune is pioneering a pipeline of unique trispecific T cell engagers with integrated CD2 costimulation.

Biotechnology · Branford$20.0M Series Unknown
Enara Bio
October 2024

Ervaxx is illuminating the immune interface to develop new cancer therapies.

Biotechnology · London$32.5M Series B
ImmunOs Therapeutics
September 2024

ImmunOs Therapeutics is a clinical-stage biotechnology company.

Biotechnology · Schlieren$11.0M Series C
Curve Therapeutics
February 2024

Curve develops an innovative screening platform.

Biotechnology · Southampton$51.4M Series A
Storm Therapeutics
December 2022

Targeting pathways that modify RNA to deliver novel cancer therapeutics

Biotechnology · Cambridge$30.0M Series B
Nucleome Therapeutics
October 2022

Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat diseases

Biotechnology · Headington$42.0M Series A
Anaveon
December 2021

Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions.

Therapeutics · Bottmingen$119.7M Series B
Kestrel Therapeutics
December 2021

Kestrel Therapeutics is a medical research and devenlopment company that offers treatment solutions for RAS cancers.

Biopharma · Allston$40.0M Series A
Anjarium Biosciences
September 2021

Anjarium is focused on creating new class of non-viral gene therapies to deliver predictable ,inclusionary ways to tackle genetic diseases.

Biotechnology · Schlieren$60.4M Series A
Montis Biosciences
June 2021

Montis Biosciences is develops novel immune-oncology therapeutics targeting the intersection between vascular dysfunction.

Biotechnology · Meise$1.2M Grant
Palleon Pharmaceuticals
September 2020

Palleon Pharmaceuticals is a developer of a biotechnology platform designed to offer glycoimmune checkpoint inhibitors to treat cancer.

Biotechnology · Waltham$100.0M Series B
Metabomed
December 2019

Metabomed designs drugs that treats cancer.

Biopharma · Yavne$12.5M Series B
Triplet Therapeutics
December 2019

Triplet is developing transformative therapies that treat repeat expansion disorders at their source.

Biotechnology · Cambridge$49.0M Series A
Mitokinin
October 2018

Mitokinin is operates in the healthcare industry focusing on biotechnology business.

Biotechnology · San Francisco$5.0M Series Unknown
NeuMoDx Molecular
May 2018

NeuMoDx Molecular, Inc. operates as a molecular diagnostics company. The company develops solutions for molecular diagnostic (MDx) testing

Biotechnology · Ann Arbor$20.0M Series Unknown
Cydan
October 2017

Cydan is an orphan drug accelerator focused on identifying and de-risking compounds with therapeutic and commercial potential.

Biotechnology · Cambridge$34.0M Series Unknown
Autifony Therapeutics
March 2017

Autifony Therapeutics is a biotechnology company developing medicines to treat hearing disorders such as hearing loss and tinnitus.

Biotechnology · London$1.6M Series Unknown

Where Pfizer Venture Investments invests

Biotechnology23
Health Care13
Medical9
Therapeutics9
Pharmaceutical5
Life Science3

About Pfizer Venture Investments's portfolio

How many companies has Pfizer Venture Investments invested in?

Pfizer Venture Investments has invested in 52 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Pfizer Venture Investments invest in?

Pfizer Venture Investments's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Pharmaceutical. The firm invests across 14 different industry categories.

What is Pfizer Venture Investments's largest investment?

Among tracked funding rounds, Anaveon received $119.7M in a Series B round. Pfizer Venture Investments's total known invested capital is $2.1B.

What is the average investment size for Pfizer Venture Investments?

Pfizer Venture Investments's average investment size is $50.3M across its portfolio of 52 companies.

What are Pfizer Venture Investments's most recent investments?

Recent Pfizer Venture Investments portfolio additions include MindImmune Therapeutics, Enodia Therapeutics, Syneron, 4D Molecular Therapeutics, Crossbow Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 52 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →